Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

View Full Paper
Ask AI
Bookmark
Share

Authors

HGHe GuangShengJLJianyong LiJSJingnan Sun

Discussion

Loading...

Member takes

Overview

Interim analysis shows LP-005 improves hemoglobin and reduces adverse events in PNH patients with active hemolysis, suggesting enhanced efficacy over traditional therapies.

Key Points

  • All 20 treated patients showed positive clinical improvements by Week 12, with significant increases in hemoglobin levels.
  • Adverse events occurred in 70% of patients, all resolving, indicating a generally favorable safety profile for LP-005 in PNH treatment.
  • Doses of LP-005 were escalated for 7 patients, which led to enhanced efficacy and better clinical outcomes.
  • The study highlights LP-005's potential superiority over single-pathway inhibitors, especially in managing hemolysis associated with PNH.

Cite This Study

GuangSheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e371https://doi.org/10.1182/blood-2025-983
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)2025
  2. 2KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.2025 · 1 citations
  3. 3VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study2025
  4. 4Efficacy and safety of NTQ5082 monotherapy in complement-inhibitor-Naïve patients with paroxysmal nocturnal hemoglobinuria: A proof-of-concept, multicenter, randomized, open-label phase 2 study2025
  5. 5The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors2025